Xin Ma

Dr. Xin Ma


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2023 in Annals of Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
GLGemingtian Liu
Gemingtian Liu
XMXin Ma
Xin Ma
YZYu Zhang
Yu Zhang
BSBoyan Su
Boyan Su
PLPinan Liu
Pinan Liu

4 December 2023 in Neurochirurgie
Verified
Journal Article
Closed access
XMXin Ma
Xin Ma
YZYu Zhang
Yu Zhang
ZYZhi-Jun Yang
Zhi-Jun Yang
WBWang Bo
Wang Bo
XWXin-Chao Wang
Xin-Chao Wang
ZBZhiyong Bi
Zhiyong Bi

13 October 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
YWYing Wang
Ying Wang
YRYuan Ren
Yuan Ren
QZQi Zhang
Qi Zhang
CZChao Zhang
Chao Zhang
MYMinjun Yan
Minjun Yan
PLPinan Liu
Pinan Liu
In-depth exploration of tumor immune suppression mechanisms may provide new therapeutic options for NF2-associated tumors. In this study, we found that sEVs secreted by NF2-associated schwannomas (NF2-EVs) facilitate the conversion of CD14+ monocytes into an MDSC-like phenotype, showcasing MDSC-like inhibitory functions. Moreover, these NF2-EVs are capable of enhancing tumor cell proliferation. Through proteomic analysis and subsequent validation of the NF2-EVs, we identified elevated levels of HSP90. When we knocked down HSP90 expression in tumor cells, the sEVs secreted showed diminished capacity to convert monocytes into MDSCs and a reduced ability to promote tumor cell proliferation. Conversely, sEVs secreted by tumor cells that overexpress HSP90 displayed the opposite effects. Further mechanistic studies revealed that HSP90 could influence the expression of AKT/p-AKT and ERK/p-ERK. Our results suggest that NF2 tumor cells could regulate the AKT/p-AKT and ERK/p-ERK pathways to promote tumor cell proliferation and the formation of an immunosuppressive microenvironment by secreting sEVs’ HSP90, offering valuable insights into the involvement of HSP90 in exosome-mediated communication within the context of NF2-related schwannomatosis (NF2-SWN). This information has the potential to inform the design of effective immunotherapeutic protocols and offer new treatment options for NF2-SWN patients.

3 September 2024 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
XMXin Ma
Xin Ma
SLShiwei Li
Shiwei Li
ZYZhijun Yang
Zhijun Yang
YZYu Zhang
Yu Zhang
HWHongyu Wu
Hongyu Wu
ZBZhiyong Bi
Zhiyong Bi

23 February 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
XMXin Ma
Xin Ma
HWHongyu Wu
Hongyu Wu
YZYu Zhang
Yu Zhang
ZYZhijun Yang
Zhijun Yang
PLPinan Liu
Pinan Liu
Background: Invasive non-functional pituitary adenomas (NFPAs) are associated with high recurrence and unfavorable clinical outcomes, yet their underlying molecular mechanisms remain incompletely understood. This study aimed to identify robust biomarkers of invasiveness by integrating transcriptional networks, machine learning, and epigenetic regulation. Methods: RNA sequencing was performed on 32 NFPA samples (15 invasive, 17 non-invasive). Weighted gene co-expression network analysis (WGCNA) was used to identify invasiveness-associated modules, which were validated in public datasets (GSE169498, GSE51618). Candidate genes were prioritized using machine learning, and their epigenetic regulation was studied using DNA methylation datasets (GSE207937, GSE115783). Results: We identified a five-gene signature associated with invasiveness (KIFC3, PNMA3, ARHGAP18, LRRC10B, and KCNC4). All five genes were consistently downregulated in invasive NFPAs (all p < 0.01) and were enriched in oxidative phosphorylation and neuroactive ligand–receptor interaction pathways. A machine learning validation approach (Random Forest followed by forward stepwise logistic regression) showed strong discriminative performance for this signature (mean AUC = 0.919). DNA methylation analyses indicated no robust differences at the genome-wide level or across promoter regions of the core genes; nevertheless, several locus-specific CpG sites (e.g., near KIFC3) showed suggestive methylation changes. Conclusions: Using an integrative multi-omics framework, we identified a novel five-gene signature associated with NFPA invasiveness. The coordinated downregulation of these genes may reflect alterations in cellular energy metabolism and microenvironmental signaling. Although the signature demonstrated promising diagnostic potential, its transcriptional repression is unlikely to be primarily explained by DNA methylation. These findings provide candidate markers and mechanistic hypotheses for understanding invasive NFPA and developing risk-stratification tools.

27 May 2026 in Current Oncology
Verified
Journal Article
Open access
PDF file
YZYu Zhang
Yu Zhang
ZMZenghua Mi
Zenghua Mi
HWHongyu Wu
Hongyu Wu
XMXin Ma
Xin Ma
LXLong Xi
Long Xi
PLPinan Liu
Pinan Liu
Background: In growth hormone-secreting pituitary adenomas (GHPA), postoperative hormonal non-remission and tumor recurrence determine clinical prognosis. Notably, some patients exhibit persistent hormonal abnormalities despite intraoperative gross total resection (GTR). This study systematically analyzes the prognostic risk factors in GHPA. Methods: This study collected clinical information from 344 GHPA patients. Univariate and multivariate regression analyses were performed to screen independent risk factors for hormonal non-remission, tumor recurrence, and hormonal non-remission after GTR. Nomograms were established for predicting hormonal non-remission and 3-/5-year recurrence probabilities. Subgroup comparisons were performed to further analyze significant risk factors. Results: Multivariate Logistic regression identified recurrent cases (p = 0.009), preoperative GH > 40 ng/mL (p = 0.043), not GTR (p < 0.001), and Knosp grade IV (p = 0.004) as independent risk factors of postoperative hormonal non-remission. For patients who underwent GTR, the recurrent status (p = 0.016) and Knosp grade III/IV (p = 0.049/0.009) remained significant risk factors for hormonal non-remission. Multivariate Cox regression showed preoperative GH > 40 ng/mL (p = 0.002), hormonal non-remission (p = 0.037), Knosp grade IV (p = 0.025), and vision defect (p = 0.010) as independent risk factors for tumor recurrence. The nomograms had good discrimination and calibration, with test set AUCs of 0.828 for hormonal non-remission, 0.82 for 3-year recurrence, and 0.859 for 5-year recurrence. Subgroup analysis revealed that recurrent cases, compared to initial cases, had younger patient ages, higher Knosp grades, harder tumor textures, and generally higher Ki-67 indices (all p < 0.05). Further analysis demonstrated that, relative to Knosp grade III tumors, grade IV lesions were larger, firmer, and associated with significantly lower rates of both GTR and hormonal remission, alongside a higher recurrence risk (all p < 0.05). Conclusions: Patients with high preoperative GH levels, higher Knosp grades, and recurrence often have a poorer prognosis after treatment. These results support stratified postoperative management and individualized monitoring of GHPA patients.